Research output per year
Research output per year
Search results
-
2024
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation
Frerichs, K. A., Verkleij, C. P. M., Mateos, M. V., Martin, T. G., Rodriguez, C., Nooka, A., Banerjee, A., Chastain, K., Perales-Puchalt, A., Stephenson, T., Uhlar, C., Kobos, R., van der Holt, B., Kruyswijk, S., Kuipers, M. T., Groen, K., Vishwamitra, D., Skerget, S., Cortes-Selva, D., Doyle, M., & 4 others, 9 Jan 2024, In: Blood. 8, 1, p. 194-206 13 p.Research output: Contribution to journal › Article › Academic › peer-review
Open Access -
2023
Correctly structured problem lists lead to better and faster clinical decision-making in electronic health records compared to non-curated problem lists: A single-blinded crossover randomized controlled trial
Klappe, E. S., Heijmans, J., Groen, K., ter Schure, J., Cornet, R. & de Keizer, N. F., 1 Dec 2023, In: International Journal of Medical Informatics. 180, 105264.Research output: Contribution to journal › Article › Academic › peer-review
Open Access -
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
COBRA KAI Study Team, 1 Jul 2023, In: EClinicalMedicine. 61, 102040.Research output: Contribution to journal › Article › Academic › peer-review
Open Access4 Citations (Scopus) -
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
Groen, K., Stege, C. A. M., Nasserinejad, K., de Heer, K., van Kampen, R. J. W., Leys, R. B. L., Thielen, N., Westerman, M., Wu, K-L., Ludwig, I., Issa, D. E., Velders, G. A., Vekemans, M-C., Timmers, G-J., de Boer, F., Tick, L. W., Verbrugge, A., Buitenhuis, D., Cunha, S. M., van der Spek, E., & 9 others, 1 Sept 2023, In: EClinicalMedicine. 63, 102167.Research output: Contribution to journal › Article › Academic › peer-review
Open Access2 Citations (Scopus) -
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
Groen, K., Schjesvold, F. H., van der Holt, B., Levin, M-D., Seefat, M. R., Hansson, M., Leys, M. B. L., Regelink, J. C., Waage, A., Szatkowski, D., Axelsson, P., Hieu Do, T., Svirskaite, A., van der Spek, E., Haukas, E., Knut-Bojanowska, D., Ypma, P. F., Blimark, C. H., Mellqvist, U-H., van de Donk, N. W. C. J., & 5 others, 30 Sept 2023, In: HemaSphere. 7, 9, p. E940Research output: Contribution to journal › Letter › Academic › peer-review
Open Access -
Treatment sequences and drug costs from diagnosis to death in multiple myeloma
Seefat, M. R., Cucchi, D. G. J., Groen, K., Donker, M. L., van der Hem, K. G., Westerman, M., Gerrits, A. M., Beeker, A., van de Donk, N. W. C. J., Blommestein, H. M. & Zweegman, S., 11 Oct 2023, (E-pub ahead of print) In: European journal of haematology.Research output: Contribution to journal › Article › Academic › peer-review
Open Access -
2022
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19
COBRA KAI Study Team, 1 Oct 2022, In: JAMA Oncology. 8, 10, p. 1477-1483 7 p.Research output: Contribution to journal › Article › Academic › peer-review
Open Access45 Citations (Scopus) -
2021
A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
Seefat, M. R., Cucchi, D. G. J., Dirven, S., Groen, K., Zweegman, S. & Blommestein, H. M., 9 Nov 2021, In: Cancers. 13, 22, 5606.Research output: Contribution to journal › Review article › Academic › peer-review
Open Access5 Citations (Scopus)